IRVINE, Calif., Nov. 16, 2017 (GLOBE NEWSWIRE) — MRI Interventions, Inc. (OTCQB:MRIC) today announced the 2000th procedure completed with the ClearPoint NeuroNavigation System. The procedure was done by Dr. William Anderson at Johns Hopkins University.
In the fall of 1998, a group of researchers at Johns Hopkins University imagined a novel MRI concept. To that point, MRI was used solely for diagnostic imaging. These pioneers envisioned a new, groundbreaking application: using the power of MRI to guide therapeutic procedures, enabling the MRI scanner to serve as the eyes of the surgeon while the procedure is being performed. The group was led by Dr. Paul Bottomley, the then head of Advanced MR Research at John Hopkins University, and included Drs. Elias Zerhouni, Ergin Atalar and Henry Halperin. Nineteen years later, the company formed as a result of this first meeting has become a global leader in real-time, MRI-guided, minimally invasive neuro-navigation.
“We are thrilled to have achieved over 550 procedures this year,” said Wendelin Maners, Vice President of Marketing and Clinical Operations, “and our milestone 2000th procedure, a DBS electrode placement, was performed where interventional MRI began, at Johns Hopkins University. With ClearPoint, surgeons use the power of MRI to plan, target, and place devices deep in the brain with exceptional accuracy and intra-procedural visualization. Functional neurosurgeons and their patients benefit every day from the pioneering work of these visionaries many years ago. The ClearPoint Neuro Navigation System is now installed in more than 50 top hospitals and research centers across the country. We thank the innovators for their work nineteen years ago, and are honored to continue their legacy in pioneering the field of interventional MRI.”
About MRI Interventions, Inc.
Building on the imaging power of magnetic resonance imaging (“MRI”), MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain. The ClearPoint Neuro Navigation System, which has received 510(k) clearance and is CE marked, utilizes a hospital’s existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com.
Statements herein concerning MRI Interventions, Inc. (the “Company”) plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company’s future events, developments and future performance, as well as management’s expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company’s actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: future revenues from sales of the Company’s ClearPoint Neuro Navigation System products; and the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, both of which have been filed with the Securities and Exchange Commission.
MRI Interventions, Inc.
Matt Kreps, Darrow Associates Investor Relations